CSIR-CDRI collaborates with Bengaluru based startup to develop novel therapeutics for cancer treatment
news
Published on 17 October 2023
CSIR-CDRI and Sravathi AI Technology Join Forces to Accelerate Cancer Therapeutics
Summary:
CSIR-Central Drug Research Institute (CSIR-CDRI), Lucknow, has entered into a strategic partnership with Bengaluru-based startup Sravathi AI Technology to fast-track the discovery of novel cancer therapeutics. Sravathi brings its cutting-edge AI and computational tools to design novel chemical entities (NCEs) with potential anti-cancer properties. CSIR-CDRI will then synthesize these candidates and conduct thorough biological evaluations both in vitro and in vivo, optimizing promising leads toward clinical candidacy.
Why this matters:
- Speed & cost-efficiency: Combining AI-driven design with CSIR-CDRI’s proven drug discovery pipeline accelerates the identification of effective, safe drug candidates—saving time and resources.
- Mission-driven impact: CSIR-CDRI, a key center in CSIR’s Pan-Cancer Mission, brings deep expertise in cancer biology and drug development, targeting cancers with high unmet need like triple-negative breast cancer.
- Tech meets science: As Dr. Kishan Gurram (Founder & MD, Sravathi) puts it: “By combining our AI capabilities with CDRI’s capacities in drug discovery, we believe that novel candidates (compounds) that are effective and safe will be identified faster and at lower cost.”
- Dr. Radha Rangarajan, Director, CSIR-CDRI, emphasizes the institute’s strong R&D legacy and its critical role in advancing Pan-Cancer goals through this collaboration.